REGENXBIO Inc. (RGNX)
NMS · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 21.4M | 29.7M | 30.3M | 6.4M |
| Gross Profit | 16.1M | 24.0M | 24.4M | -4.7M |
| Operating Income | -63.3M | -52.4M | -57.6M | -83.4M |
| Net Income | -70.9M | -61.9M | -67.1M | -90.1M |
| Diluted EPS | $-1.38 | $-1.20 | $-1.30 | $-1.72 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 112.7M | 90.2M | 83.3M | 170.4M |
| Gross Profit | 58.2M | 53.0M | 49.8M | 150.1M |
| Operating Income | -262.9M | -268.1M | -231.2M | -161.2M |
| Net Income | -280.3M | -263.5M | -227.1M | -193.9M |
| Diluted EPS | $-6.50 | $-6.02 | $-4.59 | $nan |